Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH

Y Intercept Hong Kong Ltd boosted its stake in Guardant Health, Inc. (NASDAQ:GH) by 66.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,295 shares of the company’s stock after purchasing an additional 30,526 shares during the period. Y Intercept Hong Kong Ltd owned about 0.06% of Guardant Health worth $4,767,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Emerald Advisers LLC lifted its holdings in Guardant Health by 24.8% in the third quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares during the period. Edgestream Partners L.P. grew its holdings in Guardant Health by 147.3% during the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock worth $2,629,000 after acquiring an additional 30,094 shares during the period. State of Wyoming bought a new position in shares of Guardant Health in the 2nd quarter worth about $567,000. Yorktown Management & Research Co Inc bought a new position in shares of Guardant Health in the 2nd quarter worth about $289,000. Finally, Federated Hermes Inc. lifted its stake in shares of Guardant Health by 72.4% in the 2nd quarter. Federated Hermes Inc. now owns 1,465,438 shares of the company’s stock valued at $76,261,000 after purchasing an additional 615,429 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Down 2.2%

Shares of NASDAQ GH opened at $114.75 on Monday. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74. The firm has a market capitalization of $14.46 billion, a PE ratio of -35.75 and a beta of 1.58. The firm has a fifty day simple moving average of $105.24 and a two-hundred day simple moving average of $77.82.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the business posted ($0.88) EPS. The company’s revenue was up 38.5% on a year-over-year basis. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday. Guggenheim raised their price objective on shares of Guardant Health from $85.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 7th. Finally, Morgan Stanley boosted their target price on shares of Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Twenty-one research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.81.

Insider Buying and Selling at Guardant Health

In other news, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares in the company, valued at $212,534,386.26. This trade represents a 4.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Darya Chudova sold 5,451 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $104.04, for a total value of $567,122.04. Following the sale, the chief technology officer owned 7,012 shares in the company, valued at $729,528.48. This represents a 43.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 445,123 shares of company stock worth $46,600,702. Insiders own 6.10% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.